Contraception News and Research

Latest Contraception News and Research

IPS examines potential for future U.N. population meeting

Inter Press Service examines the possibility of another U.N. conference on development and population within the next five years. Despite progress made since the 1994 conference on population and development (ICPD), U.N. Secretary-General Ban Ki-Moon recently noted more than 200 million women cannot access safe and effective contraception, and "too many women resort to unsafe abortions because they lack access to family planning," according to the news service.

20 Oct 2009

Positive data from BioSante Pharmaceuticals' LibiGel Phase III clinical development program

BioSante Pharmaceuticals, Inc., today announced positive safety data in its ongoing LibiGel Phase III clinical development program. For the first time, unblinded data have been reviewed by the independent DMC of the LibiGel Cardiovascular and Breast Cancer Safety Study. Based on this review of unblinded data, the DMC unanimously recommended continuation of the study as described in the study protocol, with no modifications.

20 Oct 2009

Novartis' Tasigna capsules meets primary endpoint in comparison trial with Gleevec

Novartis announced today that Tasigna (nilotinib) 200 mg capsules met its primary endpoint in the first head-to-head comparison with the company's groundbreaking drug Gleevec (imatinib mesylate) tablets*. Tasigna produced faster and deeper responses than Gleevec when given as first-line therapy for adult patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML) in chronic phase. Tasigna was well tolerated in the study.

20 Oct 2009

Hologic opens new facility in Hong Kong

Hologic, Inc., a leading developer, manufacturer and supplier of premium diagnostics, medical imaging systems and surgical products dedicated to serving the healthcare needs of women, today announced the opening of its new Asia Pacific regional offices and the Hologic Asia Pacific Center for Health Sciences Education in Hong Kong.

From Hologic, Inc. 19 Oct 2009

Schering-Plough to present data on boceprevir at the AASLD 2009 Annual Meeting

Schering-Plough announced that data on boceprevir, an investigational hepatitis C virus (HCV) protease inhibitor, will be reported in an oral presentation at the American Association for the Study of Liver Diseases (AASLD) Annual Meeting in Boston, Oct. 30-Nov. 3.

19 Oct 2009

Recent releases in global health

In light of a recent Guttmacher Institute report that indicated 70,000 women in developing countries die each year from unsafe abortion, a Lancet editorial outlines ways to reduce deaths, and says, "The current political climate is favourable, because the global-gag rule (the U.S. Government's policy on banning funding of foreign organisations linked to any type of abortion practice) is out of favour" (10/17).

19 Oct 2009

Also in global health news: Street pharmacies; China health care; Hospital safety; African cardinals; Cells phones for health

Agence France-Presse examines Adjegounle, the "drugs" district in Benin. Although some are able to support their families by selling drugs at "street pharmacies," a minimum of "250 deaths and 340 cases of chronic illnesses linked to such drugs were recorded between April 2007 and June 2008," according to a medical thesis, the news service writes.

19 Oct 2009

Biosante Pharmaceuticals, Cell Genesys successfully complete merger

BioSante Pharmaceuticals, Inc. and Cell Genesys, Inc., today announced the successful completion of their previously announced merger of Cell Genesys with and into BioSante, with BioSante as the surviving company, under which BioSante now has acquired all of the outstanding shares of Cell Genesys common stock.

15 Oct 2009

Abortions worldwide decline, unsafe abortions kill 70,000 women annually, report says

Fewer abortions are taking place worldwide because of increased contraceptive use, a study by the Guttmacher Institute has found, Reuters reports. The study also indicates that 20 million "unsafe abortions, mostly in poorer countries and often carried out by the women themselves using inappropriate drugs or herbal potions, or by untrained traditional healers," still occur each year and kill 70,000 women annually (Kelland, 10/13).

15 Oct 2009

Also in Global Health News: Ban addresses women's health; Afghanistan's health services; PMI Africa grants; Q&As

U.N. Secretary-General Ban Ki-Moon on Monday called for countries around the world to "renew their commitment to educate girls, end sexual violence, and provide access to modern birth control," the Associated Press/Washington Post reports.

14 Oct 2009

USAID awards Abt Associates 'Strengthening Health Outcomes Through Private Sector' grant

The United States Agency for International Development (USAID) has awarded a five-year grant, Strengthening Health Outcomes through the Private Sector, to Abt Associates, Inc. Sub-recipients under the grant are Banyan Global, Jhpiego, Marie Stopes International, the Monitor Group, and O'Hanlon Health Consulting, LLC.

13 Oct 2009

Study reveals that teenage boys are less responsible than girls in preventing chlamydia

Teenage boys in Sweden take less responsibility than girls for preventing the spread of chlamydia and other sexually transmitted infections, according to a new study from the Sahlgrenska Academy at the University of Gothenburg, Sweden.

13 Oct 2009

Birth control pills may have an impact on choice of partners

There is no doubt that modern contraception has enabled women to have unprecedented control over their own fertility. However, is it possible that the use of oral contraceptives is interfering with a woman's ability to choose, compete for and retain her preferred mate?

8 Oct 2009

Multiple intervention programs can reduce teen pregnancies

When teenagers receive health education and information about contraception, the number of them having unintended pregnancies decreases, finds a large new review.

7 Oct 2009

Schering-Plough receives FDA recommendation approval for PEGINTRON

Schering-Plough Corp. announced that the U.S. Food and Drug Administration's (FDA) Oncologic Drugs Advisory Committee (ODAC) recommended approval by a vote of six to four for PEGINTRON® (pegylated interferon alfa-2b) in the adjuvant treatment of patients with Stage III malignant melanoma.

6 Oct 2009

Jon O'Brien's statement on healthcare reform

"This Sunday, the United States Conference of Catholic Bishops holds its annual Respect Life Sunday. On this occasion, we would like to encourage the US bishops to also respect the truth. A recent publication by the USCCB, a brochure entitled Contraception: The Fine Print, and recent polls on healthcare reform prove that the bishops' desire to promote their own views on reproductive health leads them to play fast and loose with the truth.

5 Oct 2009

FDA approves Bayer's IUD Mirena for treating heavy menstrual bleeding

The U.S. Food and Drug Administration today approved Mirena (levonorgestrel intrauterine system) to treat heavy menstrual bleeding in women who use intrauterine contraception as their method of pregnancy prevention. This is the first intrauterine device approved by the FDA for this additional indication.

3 Oct 2009

HRA Pharma launches its new generation emergency contraceptive in Europe

HRA Pharma (http://www.hra-pharma.com), a privately-held, European pharmaceutical company that designs products, devices and supporting services in reproductive health and endocrinology, announced today that ellaOne(R) (ulipristal acetate, 30mg), its new generation emergency contraceptive, has been launched in France, Germany and the United Kingdom via local HRA teams. HRA Pharma will progressively launch ellaOne in all European countries over the coming months.

1 Oct 2009

Health Canada approves VIBATIV for treating complicated skin and skin structure infections

Astellas Pharma Canada, Inc. announced today that Health Canada has approved VIBATIV(TM) (telavancin) for the treatment of adult patients with complicated skin and skin structure infections (cSSSI) caused by susceptible Gram-positive bacteria, including Staphylococcus aureus, both methicillin-resistant (MRSA) and methicillin-susceptible (MSSA) strains.

1 Oct 2009

Stockholders approve BioSante Pharmaceuticals–Cell Genesys merger

BioSante Pharmaceuticals, Inc. and Cell Genesys, Inc., today announced that BioSante stockholders have approved the merger between the two companies with BioSante as the surviving company.

1 Oct 2009

Contraception News and Research

Latest Contraception News and Research

IPS examines potential for future U.N. population meeting

Positive data from BioSante Pharmaceuticals' LibiGel Phase III clinical development program

Novartis' Tasigna capsules meets primary endpoint in comparison trial with Gleevec

Hologic opens new facility in Hong Kong

Schering-Plough to present data on boceprevir at the AASLD 2009 Annual Meeting

Recent releases in global health

Also in global health news: Street pharmacies; China health care; Hospital safety; African cardinals; Cells phones for health

Biosante Pharmaceuticals, Cell Genesys successfully complete merger

Abortions worldwide decline, unsafe abortions kill 70,000 women annually, report says

Also in Global Health News: Ban addresses women's health; Afghanistan's health services; PMI Africa grants; Q&As

USAID awards Abt Associates 'Strengthening Health Outcomes Through Private Sector' grant

Study reveals that teenage boys are less responsible than girls in preventing chlamydia

Birth control pills may have an impact on choice of partners

Multiple intervention programs can reduce teen pregnancies

Schering-Plough receives FDA recommendation approval for PEGINTRON

Jon O'Brien's statement on healthcare reform

FDA approves Bayer's IUD Mirena for treating heavy menstrual bleeding

HRA Pharma launches its new generation emergency contraceptive in Europe

Health Canada approves VIBATIV for treating complicated skin and skin structure infections

Stockholders approve BioSante Pharmaceuticals–Cell Genesys merger

Precision in every drop: Inside Hamilton’s syringe technology

Exploring the Future of Neuroscience Drug Discovery

Genomic conservation in Thailand's mangroves

Contraception News and Research

Latest Contraception News and Research

Precision in every drop: Inside Hamilton’s syringe technology

Exploring the Future of Neuroscience Drug Discovery

Genomic conservation in Thailand's mangroves

Newsletters you may be interested in